Pharma Giant Seeks Bulk Drug Making Approval
Published Date: 6/5/2025
Notice
Summary
ANI Pharmaceuticals Inc. wants to get official approval to make large amounts of certain controlled drugs. This affects anyone involved in drug manufacturing and regulation, with no immediate cost changes but important for future drug supply. Keep an eye out for updates as this could impact medicine availability soon!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-10229 — Stainless Steel Flanges From India: Final Results of Antidumping Duty Administrative Review; 2022-2023
The U.S. checked stainless steel flanges from India and found they were sold in the U.S. for less than fair prices from October 2022 to September 2023. Because of this, extra duties (taxes) will apply to these flanges to keep things fair for American businesses. Importers and Indian exporters should get ready for these changes starting now.
Next: 2025-10232 — Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to the City of Whittier's Whittier Harbor Rebuild Phase III Project in Whittier, Alaska
The City of Whittier wants permission to safely work on their harbor in Alaska, which might accidentally bother some marine mammals nearby. The government is asking for public thoughts before deciding if they can give the okay, including a possible one-year extension. This project is planned soon and aims to balance construction with protecting sea life.